Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 2/20 | 0.51 |
| ▸ | CLK1 | P49759 | 2/20 | 0.51 |
| ▸ | LIMK1 | P53667 | 2/20 | 0.51 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.51 |
| ▸ | PIM1 | P11309 | 3/20 | 0.47 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.47 |
| ▸ | PIM3 | Q86V86 | 2/20 | 0.47 |
| ▸ | AURKA | O14965 | 2/20 | 0.47 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.47 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.47 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.47 |
| ▸ | RET | P07949 | 2/20 | 0.47 |
| ▸ | IGF1R | P08069 | 2/20 | 0.47 |
| ▸ | CLK2 | P49760 | 2/20 | 0.47 |
| ▸ | GSK3A | P49840 | 2/20 | 0.47 |
| ▸ | GSK3B | P49841 | 2/20 | 0.47 |
| ▸ | PRKX | P51817 | 2/20 | 0.47 |
| ▸ | BTK | Q06187 | 2/20 | 0.47 |
| ▸ | TYRO3 | Q06418 | 2/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4208864 | 0.78 | KRAS (0.51) | CDC7LIMK1PIM1CLK4PIM3 | |
| SCHEMBL10309423 | 0.77 | LIMK1 (0.45) | CDC7CLK1LIMK1DBF4PIM1 | |
| SCHEMBL2300781 | 0.77 | PIM1 (0.47) | CDC7PIM1CLK4PIM3AURKA | |
| SCHEMBL2299936 | 0.76 | LIMK1 (0.50) | CDC7CLK1LIMK1PIM1CLK4 | |
| SCHEMBL19805138 | 0.76 | LIMK1 (0.56) | CDC7LIMK1PIM1CLK4PIM3 | |
| SCHEMBL2303344 | 0.75 | HPGD (0.43) | CDC7PIM1CLK4PIM3AURKA | |
| SCHEMBL271817 | 0.75 | LIMK1 (0.41) | CDC7CLK1LIMK1DBF4IKBKB | |
| SCHEMBL23378336 | 0.75 | LIMK1 (0.55) | CDC7CLK1LIMK1DBF4PIM1 | |
| SCHEMBL14955229 | 0.74 | MEN1 (0.46) | CDC7LIMK1PIM1CLK4PIM3 | |
| SCHEMBL4217004 | 0.74 | PIM1 (0.49) | CDC7PIM1CLK4PIM3AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021095032-A1 | GLUCOSE UPTAKE INHIBITORS AND USES THEREOF | METABOMED LTD (IL) | 2021-05-20 | — | — | WO | disclosed |
| US-10988810-B2 | Methods and materials for detection of mutations | PENTABASE APS (DK) | 2021-04-27 | — | — | US | disclosed |
| EP-3350347-B1 | METHODS AND MATERIALS FOR DETECTION OF MUTATIONS | PENTABASE APS (DK) | 2021-01-20 | — | — | EP | disclosed |
| US-20190085400-A1 | METHODS AND MATERIALS FOR DETECTION OF MUTATIONS | PENTABASE APS (DK) | 2019-03-21 | — | — | US | disclosed |
| EP-2004847-B1 | OLIGONUCLEOTIDES COMPRISING SIGNALLING PAIRS AND HYDROPHOBIC NUCLEOTIDES, STEMLESS BEACONS, FOR DETECTION OF NUCLEIC ACIDS, METHYLATION STATUS AND MUTANTS OF NUCLEIC ACIDS | PENTABASE APS (DK) | 2017-05-03 | — | — | EP | disclosed |
| WO-2017045689-A1 | METHODS AND MATERIALS FOR DETECTION OF MUTATIONS | PENTABASE APS (DK) | 2017-03-23 | — | — | WO | disclosed |
| US-8133984-B2 | Oligonucleotides comprising signalling pairs and hydrophobic nucleotides, stemless beacons, for detection of nucleic acids, methylation status and mutants of nucleic acids | PENTABASE APS (DK) | 2012-03-13 | — | — | US | disclosed |
| US-7989464-B2 | mGluR1 antagonists as therapeutic agents | SCHERING CORPORATION (US) | 2011-08-02 | — | — | US | disclosed |
| EP-1765829-B1 | TRICYCLIC COMPOUNDS AND THEIR USE AS MGLUR1 ANTAGONISTS | SCHERING CORP (US) | 2010-07-07 | — | — | EP | disclosed |
| US-20100121056-A1 | PSEUDONUCLEOTIDE COMPRISING AN INTERCALATOR | HUMAN GENETIC SIGNATURES PTY. LTD. (AU) | 2010-05-13 | — | — | US | disclosed |
| US-7326712-B2 | Substituted tricyclic compounds as protein kinase inhibitors | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2008-02-05 | — | — | US | disclosed |
| US-7326713-B2 | Substituted tricyclic compound as protein kinase inhibitors | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2008-02-05 | — | — | US | disclosed |
| US-7312226-B2 | Substituted tricyclic compounds as protein kinase inhibitors | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2007-12-25 | — | — | US | disclosed |
| WO-2007104318-A2 | OLIGONUCLEOTIDES COMPRISING SIGNALLING PAIRS AND HYDROPHOBIC NUCLEOTIDES, STEMLESS BEACONS, FOR DETECTION OF NUCLEIC ACIDS, METHYLATION STATUS AND MUTANTS OF NUCLEIC ACIDS | PENTABASE APS (DK) | 2007-09-20 | — | — | WO | disclosed |
| WO-2006010568-A3 | SUBSTITUTED PYRIDO[3',2':4,5]THIENO[3,2-D]PYRIMIDINE-2,4(1 H,3H)-DIONES AND -4(3H)-ONES, PYRIDO[3',2':4,5]FURO[3,2-D]PYRIMIDINE-2,4(1 H,3H)-DIONES AND -4(3H)-ONES, AND USE THEREOF AS INHIBITORS OF TNF-ALPHA RELEASE | CURACYTE DISCOVERY GMBH (DE) | 2006-09-14 | — | — | WO | disclosed |
| WO-2006010568-A3 | SUBSTITUTED PYRIDO[3',2':4,5]THIENO[3,2-D]PYRIMIDINE-2,4(1 H,3H)-DIONES AND -4(3H)-ONES, PYRIDO[3',2':4,5]FURO[3,2-D]PYRIMIDINE-2,4(1 H,3H)-DIONES AND -4(3H)-ONES, AND USE THEREOF AS INHIBITORS OF TNF-ALPHA RELEASE | CURACYTE DISCOVERY GMBH (DE) | 2006-09-14 | — | — | WO | disclosed |
| US-20060167029-A1 | mGluR1 Antagonists as therapeutic agents | SCHERING CORPORATION | 2006-07-27 | — | — | US | disclosed |
| WO-2006010568-A2 | SUBSTITUTED PYRIDO[3',2':4,5]THIENO[3,2-D]PYRIMIDINE-2,4(1 H,3H)-DIONES AND -4(3H)-ONES, PYRIDO[3',2':4,5]FURO[3,2-D]PYRIMIDINE-2,4(1 H,3H)-DIONES AND -4(3H)-ONES, AND USE THEREOF AS INHIBITORS OF TNF-ALPHA RELEASE | CURACYTE DISCOVERY GMBH (DE) | 2006-02-02 | — | — | WO | disclosed |
| WO-2006010568-A2 | SUBSTITUTED PYRIDO[3',2':4,5]THIENO[3,2-D]PYRIMIDINE-2,4(1 H,3H)-DIONES AND -4(3H)-ONES, PYRIDO[3',2':4,5]FURO[3,2-D]PYRIMIDINE-2,4(1 H,3H)-DIONES AND -4(3H)-ONES, AND USE THEREOF AS INHIBITORS OF TNF-ALPHA RELEASE | CURACYTE DISCOVERY GMBH (DE) | 2006-02-02 | — | — | WO | disclosed |
| US-20060009477-A1 | mGluR1 antagonists as therapeutic agents | SCHERING CORPORATION | 2006-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100121056-A1 | PSEUDONUCLEOTIDE COMPRISING AN INTERCALATOR | POLRMT, POLN, RNASE1 | CDC7 1072/4885CLK1 2752/4885LIMK1 4581/4885 |
| US-20060167029-A1 | mGluR1 Antagonists as therapeutic agents | GRM1, GRM4, GRIA1 | CDC7 4254/4885CLK1 3660/4885LIMK1 3031/4885 |
| US-20060009477-A1 | mGluR1 antagonists as therapeutic agents | GRM1, GRM4, GRIA1 | CDC7 4260/4885CLK1 3557/4885LIMK1 2990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.